Avacta Advances Second Clinical Candidate with Phase 1 Trial Launch
Event summary
- Avacta dosed the first patient in its Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103), a sustained-release exatecan peptide drug conjugate.
- The trial will enroll approximately 144 patients across four solid tumor types: pancreatic, cervical/vulvar, gastric/gastroesophageal junction, and small cell lung cancer.
- Avacta recently raised £10 million to extend its cash runway into early Q1 2027, covering initial data readouts for AVA6103.
- The trial uses a Bayesian Optimal Interval (BOIN) design to accelerate dose-finding and data collection.
The big picture
Avacta's progress with AVA6103 underscores the growing trend of peptide drug conjugates as alternatives to antibody-based therapies, offering targeted delivery with reduced systemic toxicity. The use of AI-driven patient selection through its Tempus AI collaboration highlights the increasing role of data analytics in oncology drug development. With £10 million in fresh funding, Avacta aims to position its pre|CISION® platform as a versatile delivery system for multiple high-potency payloads, potentially broadening its market opportunity beyond exatecan.
What we're watching
- Trial Execution
- Whether the Bayesian design can efficiently identify optimal dosing schedules while minimizing patient exposure to subtherapeutic or toxic doses.
- Data Readouts
- The pace at which initial safety and efficacy data from FOCUS-01 will influence investor confidence and potential partnerships.
- Platform Expansion
- How Avacta leverages the Gen Two sustained-release mechanism to attract additional payloads and expand its pipeline beyond exatecan.
Related topics